Parkman Healthcare Partners LLC Has $4.12 Million Stock Holdings in Pulmonx Corporation $LUNG

Key Points

• Parkman Healthcare Partners LLC significantly increased its stake in Pulmonx Corporation by 194.4%, owning 611,875 shares valued at approximately $4.1 million.
• Wall Street analysts have reduced their price targets for Pulmonx, with notable firms like Stifel Nicolaus and Piper Sandler lowering targets to $5.00 and $2.50, respectively.
• Pulmonx reported a revenue of $23.86 million for the last quarter, surpassing analyst estimates, despite posting an earnings per share of ($0.38).

Parkman Healthcare Partners LLC lifted its stake in shares of Pulmonx Corporation (NASDAQ:LUNG - Free Report) by 194.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 611,875 shares of the company's stock after purchasing an additional 404,022 shares during the period. Parkman Healthcare Partners LLC owned 1.52% of Pulmonx worth $4,118,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in LUNG. Wells Fargo & Company MN raised its stake in shares of Pulmonx by 48.7% during the 4th quarter. Wells Fargo & Company MN now owns 18,418 shares of the company's stock worth $125,000 after purchasing an additional 6,033 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Pulmonx by 17.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 408,022 shares of the company's stock worth $2,770,000 after purchasing an additional 60,489 shares in the last quarter. Stifel Financial Corp bought a new stake in shares of Pulmonx during the 4th quarter worth approximately $81,000. Northern Trust Corp raised its stake in shares of Pulmonx by 2.9% during the 4th quarter. Northern Trust Corp now owns 372,659 shares of the company's stock worth $2,530,000 after purchasing an additional 10,433 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Pulmonx during the 4th quarter worth approximately $557,000. Institutional investors own 91.04% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on LUNG. Citigroup decreased their target price on Pulmonx from $6.50 to $4.15 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Piper Sandler lowered Pulmonx from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $9.00 to $2.50 in a report on Thursday, July 31st. Lake Street Capital decreased their target price on Pulmonx from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday, July 31st. D. Boral Capital reissued a "buy" rating and set a $16.00 target price on shares of Pulmonx in a report on Monday. Finally, Stifel Nicolaus decreased their target price on Pulmonx from $16.00 to $5.00 and set a "buy" rating on the stock in a report on Thursday, July 31st. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $7.66.

Insider Transactions at Pulmonx

In related news, Director Richard Ferrari sold 8,000 shares of the business's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $3.16, for a total value of $25,280.00. Following the completion of the sale, the director directly owned 87,024 shares in the company, valued at $274,995.84. The trade was a 8.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 41,896 shares of company stock valued at $79,514. Insiders own 6.80% of the company's stock.

Pulmonx Stock Performance

LUNG traded down $0.01 during trading on Tuesday, hitting $1.69. The stock had a trading volume of 424,157 shares, compared to its average volume of 627,373. The company has a 50 day moving average price of $2.21 and a 200-day moving average price of $4.03. The firm has a market cap of $68.87 million, a price-to-earnings ratio of -1.18 and a beta of 0.43. Pulmonx Corporation has a one year low of $1.47 and a one year high of $9.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.35 and a quick ratio of 4.63.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02. The business had revenue of $23.86 million during the quarter, compared to the consensus estimate of $23.46 million. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%. Pulmonx has set its FY 2025 guidance at EPS. As a group, research analysts predict that Pulmonx Corporation will post -1.55 EPS for the current year.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.